Skip to main content
Top
Published in: Journal of Endocrinological Investigation 9/2015

01-09-2015 | Original Article

Does segmental body composition differ in women with Prader–Willi syndrome compared to women with essential obesity?

Authors: G. Bedogni, G. Grugni, G. Tringali, N. Marazzi, A. Sartorio

Published in: Journal of Endocrinological Investigation | Issue 9/2015

Login to get access

Abstract

Background

Subjects with Prader–Willi syndrome (PWS) have a higher fat mass and a lower fat-free mass compared to subjects with essential obesity. However, few data are presently available on the segmental body composition (BC) of PWS subjects.

Aim

To evaluate whether women with PWS and women with essential obesity, matched for age and percent body fat, differ in segmental fat distribution and surrogate markers of cardiometabolic disease (CMD).

Subjects and methods

35 women with PWS and 50 women with essential obesity were matched for age and percent body fat using coarsened exact matching. BC was measured by dual-energy X-ray absorptiometry. Oral glucose tolerance testing and measurements of cholesterol, triglycerides, C-reactive protein, and blood pressure were performed. Comparisons between PWS and obese women were performed using generalized linear models.

Results

Trunk fat was lower in PWS than in obese women on both absolute [−7.3 (95 % confidence interval −9.4 to −5.2) kg] and relative [−4.1 (−6.9 to −1.4) % of body fat] grounds. PWS and obese women had similar surrogate markers of CMD, with the exception of HDL-cholesterol, which was higher in PWS women.

Conclusion

Trunk fat is lower in obese women with PWS than in those with essential obesity. Surrogate markers of CMD are, however, mostly similar in the two groups.
Literature
1.
2.
go back to reference Brambilla P, Bosio L, Manzoni P et al (1997) Peculiar body composition in patients with Prader–Labhart–Willi syndrome. Am J Clin Nutr 65:1369–1374PubMed Brambilla P, Bosio L, Manzoni P et al (1997) Peculiar body composition in patients with Prader–Labhart–Willi syndrome. Am J Clin Nutr 65:1369–1374PubMed
3.
go back to reference Theodoro MF, Talebizadeh Z, Butler MG (2006) Body composition and fatness patterns in Prader–Willi syndrome: comparison with simple obesity. Obesity 14:1685–1690CrossRefPubMed Theodoro MF, Talebizadeh Z, Butler MG (2006) Body composition and fatness patterns in Prader–Willi syndrome: comparison with simple obesity. Obesity 14:1685–1690CrossRefPubMed
4.
go back to reference Forbes GB (1997) A distinctive obesity: body composition provides the clue. Am J Clin Nutr 65:1540–1541PubMed Forbes GB (1997) A distinctive obesity: body composition provides the clue. Am J Clin Nutr 65:1540–1541PubMed
5.
go back to reference Després J-P (2012) Body fat distribution and risk of cardiovascular disease: an update. Circulation 126:1301–1313CrossRefPubMed Després J-P (2012) Body fat distribution and risk of cardiovascular disease: an update. Circulation 126:1301–1313CrossRefPubMed
6.
go back to reference Whittington JE, Holland AJ, Webb T et al (2001) Population prevalence and estimated birth incidence and mortality rate for people with Prader–Willi syndrome in one UK health region. J Med Genet 38:792–798PubMedCentralCrossRefPubMed Whittington JE, Holland AJ, Webb T et al (2001) Population prevalence and estimated birth incidence and mortality rate for people with Prader–Willi syndrome in one UK health region. J Med Genet 38:792–798PubMedCentralCrossRefPubMed
7.
go back to reference Goldstone AP, Thomas EL, Brynes AE et al (2001) Visceral adipose tissue and metabolic complications of obesity are reduced in Prader–Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 86:4330–4338CrossRefPubMed Goldstone AP, Thomas EL, Brynes AE et al (2001) Visceral adipose tissue and metabolic complications of obesity are reduced in Prader–Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 86:4330–4338CrossRefPubMed
8.
go back to reference Thomas EL, Saeed N, Hajnal JV et al (1998) Magnetic resonance imaging of total body fat. J Appl Physiol 85:1778–1785PubMed Thomas EL, Saeed N, Hajnal JV et al (1998) Magnetic resonance imaging of total body fat. J Appl Physiol 85:1778–1785PubMed
9.
go back to reference Sode-Carlsen R, Farholt S, Rabben KF et al (2010) Body composition, endocrine and metabolic profiles in adults with Prader–Willi syndrome. Growth Horm IGF Res 20:179–184CrossRefPubMed Sode-Carlsen R, Farholt S, Rabben KF et al (2010) Body composition, endocrine and metabolic profiles in adults with Prader–Willi syndrome. Growth Horm IGF Res 20:179–184CrossRefPubMed
10.
go back to reference l’Allemand D, Eiholzer U, Schlumpf M, et al (2000) Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader–Willi syndrome. Eur J Pediatr 159:835–842 l’Allemand D, Eiholzer U, Schlumpf M, et al (2000) Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader–Willi syndrome. Eur J Pediatr 159:835–842
11.
go back to reference Kennedy L, Bittel DC, Kibiryeva N et al (2006) Circulating adiponectin levels, body composition and obesity-related variables in Prader–Willi syndrome: comparison with obese subjects. Int J Obes Relat Metab Disord 30:382–387CrossRef Kennedy L, Bittel DC, Kibiryeva N et al (2006) Circulating adiponectin levels, body composition and obesity-related variables in Prader–Willi syndrome: comparison with obese subjects. Int J Obes Relat Metab Disord 30:382–387CrossRef
12.
go back to reference Viardot A, Sze L, Purtell L et al (2010) Prader–Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance. J Clin Endocrinol Metab 95:3392–3399CrossRefPubMed Viardot A, Sze L, Purtell L et al (2010) Prader–Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance. J Clin Endocrinol Metab 95:3392–3399CrossRefPubMed
13.
go back to reference Bedogni G, Grugni G, Tringali G et al (2014) Assessment of fat-free mass from bioelectrical impedance analysis in obese women with Prader–Willi syndrome. Ann Hum Biol 26:1–5 [Epub ahead of print] Bedogni G, Grugni G, Tringali G et al (2014) Assessment of fat-free mass from bioelectrical impedance analysis in obese women with Prader–Willi syndrome. Ann Hum Biol 26:1–5 [Epub ahead of print]
14.
go back to reference Bedogni G, Grugni G, Nobili V et al (2014) Is non-alcoholic fatty liver disease less frequent among women with Prader–Willi syndrome. Obes Facts 7:71–76CrossRefPubMed Bedogni G, Grugni G, Nobili V et al (2014) Is non-alcoholic fatty liver disease less frequent among women with Prader–Willi syndrome. Obes Facts 7:71–76CrossRefPubMed
15.
go back to reference Bedogni G, Gastaldelli A, Tiribelli C et al (2014) Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. J Endocrinol Invest 37:739–744CrossRefPubMed Bedogni G, Gastaldelli A, Tiribelli C et al (2014) Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. J Endocrinol Invest 37:739–744CrossRefPubMed
16.
go back to reference Blackwell M, Iacus S, King G et al (2009) CEM: coarsened exact matching in Stata. Stata J 9:524–546 Blackwell M, Iacus S, King G et al (2009) CEM: coarsened exact matching in Stata. Stata J 9:524–546
17.
go back to reference Hind K, Oldroyd B (2013) In-vivo precision of the GE Lunar iDXA densitometer for the measurement of appendicular and trunk lean and fat mass. Eur J Clin Nutr 67:1331–1333CrossRefPubMed Hind K, Oldroyd B (2013) In-vivo precision of the GE Lunar iDXA densitometer for the measurement of appendicular and trunk lean and fat mass. Eur J Clin Nutr 67:1331–1333CrossRefPubMed
18.
go back to reference Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRefPubMed Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRefPubMed
19.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
20.
go back to reference Gastaldelli A, Ferrannini E, Miyazaki Y et al (2004) Beta-cell dysfunction and glucose intolerance: results from the san antonio metabolism (SAM) study. Diabetologia 47:31–39CrossRefPubMed Gastaldelli A, Ferrannini E, Miyazaki Y et al (2004) Beta-cell dysfunction and glucose intolerance: results from the san antonio metabolism (SAM) study. Diabetologia 47:31–39CrossRefPubMed
21.
go back to reference Iacus SM, King G, Porro G (2011) Multivariate matching methods that are monotonic imbalance bounding. J Am Stat Assoc 106:345–361CrossRef Iacus SM, King G, Porro G (2011) Multivariate matching methods that are monotonic imbalance bounding. J Am Stat Assoc 106:345–361CrossRef
22.
go back to reference Wells JCK (2012) Sexual dimorphism in body composition across human populations: associations with climate and proxies for short- and long-term energy supply. Am J Hum Biol 24:411–419CrossRefPubMed Wells JCK (2012) Sexual dimorphism in body composition across human populations: associations with climate and proxies for short- and long-term energy supply. Am J Hum Biol 24:411–419CrossRefPubMed
23.
go back to reference Lohman TG, Going SB (2006) Body composition assessment for development of an international growth standard for preadolescent and adolescent children. Food Nutr Bull 27:S314–S325PubMed Lohman TG, Going SB (2006) Body composition assessment for development of an international growth standard for preadolescent and adolescent children. Food Nutr Bull 27:S314–S325PubMed
24.
go back to reference Sode-Carlsen R, Farholt S, Rabben KF et al (2010) One year of growth hormone treatment in adults with Prader–Willi syndrome improves body composition: results from a randomized, placebo-controlled study. J Clin Endocrinol Metab 95:4943–4950CrossRefPubMed Sode-Carlsen R, Farholt S, Rabben KF et al (2010) One year of growth hormone treatment in adults with Prader–Willi syndrome improves body composition: results from a randomized, placebo-controlled study. J Clin Endocrinol Metab 95:4943–4950CrossRefPubMed
25.
go back to reference Sode-Carlsen R, Farholt S, Rabben KF et al (2012) Growth hormone treatment in adults with Prader–Willi syndrome: the Scandinavian study. Endocrine 41:191–199CrossRefPubMed Sode-Carlsen R, Farholt S, Rabben KF et al (2012) Growth hormone treatment in adults with Prader–Willi syndrome: the Scandinavian study. Endocrine 41:191–199CrossRefPubMed
26.
go back to reference Oto Y, Tanaka Y, Abe Y et al (2014) Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader–Willi syndrome. Am J Med Genet A 164A:671–675CrossRefPubMed Oto Y, Tanaka Y, Abe Y et al (2014) Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader–Willi syndrome. Am J Med Genet A 164A:671–675CrossRefPubMed
27.
go back to reference Tanaka Y, Abe Y, Oto Y et al (2013) Characterization of fat distribution in Prader–Willi syndrome: relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A 161A:27–33CrossRefPubMed Tanaka Y, Abe Y, Oto Y et al (2013) Characterization of fat distribution in Prader–Willi syndrome: relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A 161A:27–33CrossRefPubMed
28.
go back to reference Grugni G, Crinò A, Bedogni G et al (2013) Metabolic syndrome in adult patients with Prader–Willi syndrome. Nutr Metab Cardiovasc Dis 23:1134–1140CrossRefPubMed Grugni G, Crinò A, Bedogni G et al (2013) Metabolic syndrome in adult patients with Prader–Willi syndrome. Nutr Metab Cardiovasc Dis 23:1134–1140CrossRefPubMed
29.
go back to reference Brambilla P, Crinò A, Bedogni G et al (2011) Metabolic syndrome in children with Prader–Willi syndrome: the effect of obesity. Nutr Metab Cardiovasc Dis 21:269–276PubMed Brambilla P, Crinò A, Bedogni G et al (2011) Metabolic syndrome in children with Prader–Willi syndrome: the effect of obesity. Nutr Metab Cardiovasc Dis 21:269–276PubMed
30.
go back to reference Faienza MF, Ventura A, Lauciello R et al (2012) Analysis of endothelial protein C receptor gene and metabolic profile in Prader–Willi syndrome and obese subjects. Obesity 20:1866–1870CrossRefPubMed Faienza MF, Ventura A, Lauciello R et al (2012) Analysis of endothelial protein C receptor gene and metabolic profile in Prader–Willi syndrome and obese subjects. Obesity 20:1866–1870CrossRefPubMed
Metadata
Title
Does segmental body composition differ in women with Prader–Willi syndrome compared to women with essential obesity?
Authors
G. Bedogni
G. Grugni
G. Tringali
N. Marazzi
A. Sartorio
Publication date
01-09-2015
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 9/2015
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0266-y

Other articles of this Issue 9/2015

Journal of Endocrinological Investigation 9/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.